

Alabama Department of Public Health
Alabama Emergency Response Technology (ALERT)
Health Alert Network (HAN)
November 28, 2023

Paxlovid and Lagevrio Transition to the Commercial Market

Paxlovid and Lagevrio are now available for commercial purchase through pharmaceutical wholesalers. The government purchased distribution program for Lagevrio has ended and the distribution of government purchased Paxlovid will end December 15, 2023. Until then, providers with uninsured or uninsured patients can request Paxlovid through the out-of-cycle process if HPOP reporting shows inventory has been depleted.

Pfizer and Merck have patient copay savings programs for Paxlovid and Lagevrio, respectively, which can be found on their websites, <https://www.paxlovid.com/enroll-in-co-pay-program> and <https://www.merckhelps.com/programs.aspx>. In addition, a Paxlovid patient assistance program will be released December 1, 2023. See the graph below for information on how a pharmacy can enroll in this program.

Product	Programs	Description and Additional Information
Lagevrio	Patient Assistance Program	Information available November 17, 2023 Tel: 800-727-5400
	Bulk Replacement Program	Tel: 888-727-8180 Website: merckhelps.com
Paxlovid	Available November 1, 2023:	Information available November 1, 2023
	Co-Pay Savings Program	Co-Pay Savings Program will be available for eligible commercially insured patients
Paxlovid	Available December 1, 2023:	Information available December 1, 2023
	Patient Assistance Program using USG supply	Website: For Patients https://www.paxlovid.com/ Tel: 1-877-219-7225 (1-877-C19-PACK) Through December 31, 2024: Anyone uninsured or covered by federal programs, such as Medicare or Medicaid, can receive USG-procured, NDA-labeled Paxlovid at no cost through the USG PAP operated by Pfizer. Through this program, participating PAP dispensing sites will be reimbursed for any product dispensed, along with a dispensing fee. For retail pharmacies that would like to learn more about participating in the U.S. Government PAP, please contact the program vendor at PharmacyNetworkContract102101@assistrx.com . Starting January 1, 2025: Eligible uninsured and underinsured patients can receive USG procured, NDA-labeled Paxlovid at no cost. Through this program, participating PAP dispensing sites will be reimbursed for any product dispensed, along with a dispensing fee.

Pharmacies and other COVID-19 therapeutic providers should continue reporting inventory and utilization of government purchased Paxlovid and Lagevrio twice a month in HPOP until inventory is depleted. Commercially purchased product should not be reported in HPOP.

More information regarding the transition of Paxlovid and Lagevrio to the commercial market can be found at <https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/COVID19-Tx-Transition-Guide.aspx>